Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.63 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 9/20 | 0.48 |
| ▸ | CTSK | P43235 | 8/20 | 0.48 |
| ▸ | CTSB | P07858 | 6/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29168032 | 1.00 | CTSL (0.63) | CTSLJAK3BTKCTSSCTSK | |
| SCHEMBL30714052 | 1.00 | CTSL (0.63) | CTSLJAK3BTKCTSSCTSK | |
| SCHEMBL269355 | 0.89 | JAK3 (0.52) | CTSLJAK3BTKCTSSCTSK | |
| SCHEMBL20028697 | 0.89 | JAK3 (0.48) | CTSLJAK3BTKCTSSCTSK | |
| SCHEMBL5382110 | 0.87 | CTSS (0.63) | CTSLJAK3BTKCTSSCTSK | |
| SCHEMBL2851851 | 0.87 | CTSS (0.63) | CTSLJAK3BTKCTSSCTSK | |
| SCHEMBL6345086 | 0.86 | JAK3 (0.51) | CTSLJAK3BTKCTSSCTSK | |
| SCHEMBL268923 | 0.86 | JAK3 (0.51) | CTSLJAK3BTKCTSSCTSK | |
| SCHEMBL1204211 | 0.86 | JAK3 (0.61) | CTSLJAK3BTKCTSSCTSK | |
| SCHEMBL6557659 | 0.86 | JAK3 (0.61) | CTSLJAK3BTKCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092033-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| WO-2025262192-A1 | QUINAZOLINE DERIVATIVES SUITABLE FOR USE AS WERNER SYNDROME HELICASE PROTEIN INHIBITORS | BREAKPOINT THERAPEUTICS GMBH (DE) | 2025-12-26 | — | — | WO | disclosed |
| US-12421188-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-09-23 | — | — | US | disclosed |
| US-12415782-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-09-16 | — | — | US | disclosed |
| US-12404237-B2 | Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-09-02 | — | — | US | disclosed |
| US-20250243158-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-31 | — | — | US | disclosed |
| US-20250243156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-31 | — | — | US | disclosed |
| US-20250243157-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-31 | — | — | US | disclosed |
| EP-4578853-A2 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-3917616-B1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2025-06-11 | — | — | EP | disclosed |
| US-20240360080-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-31 | — | — | US | disclosed |
| US-20240300936-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2024-09-12 | — | — | US | disclosed |
| EP-4352049-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | Avelos Therapeutics Inc. (KR) | 2024-04-17 | — | — | EP | disclosed |
| US-20230040770-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2023-02-09 | — | — | US | disclosed |
| WO-2022260441-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360080-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, MCHR2 | CTSL 2910/4885JAK3 3083/4885BTK 2934/4885 |
| US-20250243157-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, MCHR2 | CTSL 2910/4885JAK3 3083/4885BTK 2934/4885 |
| US-20230040770-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, MCHR2 | CTSL 2910/4885JAK3 3083/4885BTK 2934/4885 |
| US-20260092033-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, MTNR1B | CTSL 1433/4885JAK3 2375/4885BTK 3496/4885 |
| US-12404237-B2 | Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives | HCRTR2, HCRTR1, NTSR2 | CTSL 2608/4885JAK3 2836/4885BTK 2722/4885 |
| US-12415782-B2 | Heterocyclic compound and use thereof | HCRTR2, HCRTR1, MCHR2 | CTSL 2910/4885JAK3 3083/4885BTK 2934/4885 |
| US-20250243158-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, MCHR2 | CTSL 2910/4885JAK3 3083/4885BTK 2934/4885 |
| US-20250243156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, MCHR2 | CTSL 2910/4885JAK3 3083/4885BTK 2934/4885 |
| US-20240300936-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | MAST1, MAST3, MAST4 | CTSL 643/4885JAK3 795/4885BTK 405/4885 |
| US-12421188-B2 | Heterocyclic compound and use thereof | HCRTR2, HCRTR1, MCHR2 | CTSL 2910/4885JAK3 3083/4885BTK 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.